SAB Biotherapeutics 2024 Q4 Earnings Significant Loss Widening Despite Revenue Decline

SAB Biotherapeutics reported its fiscal 2024 Q4 earnings on August 7, 2025, showing a sharp decline in both revenue and profitability. The company’s results reflected ongoing operational challenges, with losses deepening significantly compared to the prior year. While the CEO emphasized strategic initiatives to strengthen its market position, the financial performance underscored the need for continued investment and cost optimization.

Revenue
The company’s total revenue for 2024 Q4 declined by 62.4% to $114,698, a significant drop from $305,011 in the same period of 2023.

Earnings/Net Income
SAB Biotherapeutics posted a per-share loss of $1.23 in Q4 2024, compared to a loss of $0.25 in Q4 2023, representing a 395.0% increase in losses. However, the company managed to narrow its overall net loss to $-11.39 million in Q4 2024, a 50.1% reduction from the $-22.86 million reported in Q4 2023.

Price Action
The stock price of SAB Biotherapeutics has experienced mixed movements, with a 0.22% decline in the latest trading day, but a 18.62% surge during the most recent full trading week. However, it has dropped 13.57% month-to-date.

Post-Earnings Price Action Review
The strategy of buying SABS when earnings beat and selling after 30 days resulted in a significant loss. This approach had a return of -96.44%, far below the benchmark return of 38.50%, with an excess return of -134.94% and a CAGR of -58.76%. The strategy also exhibited a high maximum drawdown of 0.00% and sharp volatility of 118.48%, indicating its high-risk nature.

CEO Commentary
The CEO expressed a cautious outlook, acknowledging the Q4 2024 results of $114.698 million in revenue, an EPS of -$1.2267, and a net loss of -$11.39 million. He emphasized the company’s focus on strategic investments to strengthen its position in the life sciences research market, including expanding its product portfolio in recombinant proteins, ELISA kits, and antibody development. The CEO also highlighted the importance of enhancing R&D and global distribution capabilities to better serve academic and biotech clients.

Guidance
The company did not provide specific quantitative guidance for 2025 but outlined its intention to prioritize product innovation, market expansion, and international sales. It aims to improve profitability through production efficiency and leveraging its extensive product catalog to meet demand in key therapeutic and research areas.

Additional News
Recent non-earnings-related developments include:
1. Technology Advancement: OpenAI's launch of GPT-5 marked a significant milestone in AI capabilities, with implications across multiple industries.
2. Corporate Leadership: BMW’s former electric vehicle design head has joined Xiaomi, signaling a potential shift in strategic focus for the Chinese automaker.
3. Policy Development: The Chinese government announced plans to expand free preschool education, aiming to benefit up to 12 million children by the fall of 2025.